← Back to Search

Monoclonal Antibodies

Cohort J3 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 and day 14

Awards & highlights

Study Summary

This trial tests the safety and tolerability of a new drug in healthy Japanese people. #health #medicine

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 and day 14

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 and day 14

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 and day 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of deaths

Number of participants with AEs

Number of participants with adverse events (AEs) leading to discontinuation

+5 more

Secondary outcome measures

Area under the concentration-time curve within a dosing interval (AUC[TAU])

Maximum observed plasma concentration (Cmax)

Time of maximum observed plasma concentration (Tmax)

Trial Design

3Treatment groups

Experimental Treatment

Group I: Cohort J3Experimental Treatment2 Interventions

Group II: Cohort J2Experimental Treatment2 Interventions

Group III: Cohort J1Experimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BMS-986322

2022

Completed Phase 1

~330

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,476 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial include geriatric participants?

"This research study invites individuals aged 18 and over but below the age of 60 to enroll."

Answered by AI

Has Cohort J2 acquired the necessary regulatory approval from the FDA?

"Due to the limited data on Cohort J2's efficacy and safety, it received a rating of 1 on our team's scale. This is expected because this trial falls under Phase 1."

Answered by AI

Is the recruitment phase of this experiment still ongoing?

"Affirmative. Clinicaltrials.gov attests that, since its posting on September 28th 2022, this trial has been actively seeking candidates. Currently, 24 patients must be recruited from 1 centre for the study to progress further."

Answered by AI

How many individuals have signed up for participation in this experiment?

"Affirmative, clinicaltrials.gov confirms that this medical study is actively recruiting participants. It was initially posted on September 28th 2022 and had its most recent edit made February 8th 2023. Around 24 individuals are needed from a single site in order to have the trial completed."

Answered by AI

Who qualifies for enrollment in this clinical research program?

"This clinical trial is accepting 24 individuals between the age bracket of 18 to 60 who are in good health. To be eligible, applicants must possess no clinically significant abnormalities regarding their medical history or physical examinations, ECGs, and laboratory determinations. Furthermore, female participants should not have any potential for childbearing while all candidates need to be ethnically Japanese (with both parents being native)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

2022. "A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05546151.